| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2021 | IRWD Ironwood Pharmaceuticals Inc | Shetzline Michael67 | CMO, SVP &Head Of Drug Devt. | Sell | 4,439 | $9.11 | $40,439.29 | -1.3% | - | - | |
| Feb 26, 2021 | LNTH Lantheus Holdings, Inc. | Maeusli Heinz Christoph | Director | Buy | 1,000 | $18.02 | $18,020.00 | +7.0% | - | - | |
| Feb 26, 2021 | IRWD Ironwood Pharmaceuticals Inc | Kilroy Conor | SVP, GC &Secretary | Sell | 6,989 | $9.11 | $63,669.79 | -1.4% | - | - | |
| Feb 26, 2021 | IRWD Ironwood Pharmaceuticals Inc | Mallon Mark | Chief Executive Officer | Sell | 30,675 | $9.11 | $279,449.25 | -3.1% | - | - | |
| Feb 26, 2021 | IRWD Ironwood Pharmaceuticals Inc | Rickard Jason65 | SVP, Chief Operating Officer | Sell | 13,651 | $9.11 | $124,360.61 | -1.1% | - | - | |
| Feb 25, 2021 | ZTS Zoetis Inc. | Peck Kristin C66 | Chief Executive Officer | Sell | 16,427 | $158.37 | $2,601,476.31 | -18.8% | +12.2% | +25.1% | |
| Feb 25, 2021 | IRWD Ironwood Pharmaceuticals Inc | Owens Edward P | Director | Buy | 12,000 | $9.20 | $110,370.00 | +2.9% | - | - | |
| Feb 22, 2021 | BCRX Biocryst Pharmaceuticals Inc | Sheridan William P67 | Senior VP - CMO | Sell | 41,250 | $11.57 | $477,262.50 | -78.2% | - | - | |
| Feb 22, 2021 | YCBD Cbdmd, Inc. | Coffman Raymond Scott | Co-ceo, President, Director | Sell | 125,000 | $4.25 | $531,650.70 | -50.6% | -28.6% | -82.1% | |
| Feb 22, 2021 | BUDZ Weed, Inc. | Breen Nicole M | Secretary/ Treasurer | Sell | 19,608 | $1.10 | $21,549.20 | - | - | - | |
| Feb 19, 2021 | ZTS Zoetis Inc. | Scully Robert W | Director | Buy | 7,590 | $164.68 | $1,249,931.00 | +93.9% | +10.0% | +20.2% | |
| Feb 19, 2021 | ZTS Zoetis Inc. | Alaix Juan Ramon | Director | Sell | 133,070 | $160.55 | $21,363,972.78 | -15.7% | +10.0% | +20.2% | |
| Feb 19, 2021 | ZTS Zoetis Inc. | Lagano Roxanne70 | Executive Vice President | Sell | 6,000 | $167.88 | $1,007,280.00 | -12.5% | +10.0% | +20.2% | |
| Feb 19, 2021 | LNTH Lantheus Holdings, Inc. | Maeusli Heinz Christoph | Director | Buy | 1,000 | $19.39 | $19,390.00 | +7.6% | - | - | |
| Feb 19, 2021 | YCBD Cbdmd, Inc. | Sumichrast Martin A.83 | Chairman &Co-ceo | Sell | 395,600 | $4.43 | $1,753,502.96 | -40.0% | -32.1% | -80.6% | |
| Feb 18, 2021 | ZTS Zoetis Inc. | Chen Heidi C.47 | Executive Vice President | Sell | 600 | $170.04 | $102,024.00 | -2.4% | +2.1% | +14.6% | |
| Feb 18, 2021 | ORGO Organogenesis Holdings Inc. | Gillheeney Gary S.73 | President And CEO | Sell | 106,038 | $13.28 | $1,408,617.53 | -18.6% | - | - | |
| Feb 18, 2021 | AMPH Amphastar Pharmaceuticals, Inc. | Zhang Jack Y.45 | CEO &Chief Scientific Officer | Sell | 30,467 | $18.59 | $566,315.49 | -0.1% | +8.0% | +42.8% | |
| Feb 17, 2021 | ZTS Zoetis Inc. | Trawicki Roman48 | Executive Vice President | Sell | 4,491 | $165.82 | $744,697.62 | -55.3% | +0.9% | +14.9% | |
| Feb 17, 2021 | BTAI Bioxcel Therapeutics, Inc. | O'Neill Vincent86 | Chief Medical Officer | Sell | 25,000 | $55.58 | $1,389,459.15 | -33.1% | - | - | |
| Feb 16, 2021 | BTAI Bioxcel Therapeutics, Inc. | Yocca Frank88 | Chief Scientific Officer | Sell | 15,000 | $57.68 | $865,153.12 | -2.7% | - | - | |
| Feb 16, 2021 | ZTS Zoetis Inc. | David Glenn | Chief Financial Officer | Sell | 26,285 | $168.92 | $4,439,964.75 | -24.3% | +2.5% | +18.0% | |
| Feb 16, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Fridriksdottir Hafrun47 | Executive VP, Global R&D | Sell | 2,098 | $11.12 | $23,335.84 | -2.0% | - | - | |
| Feb 16, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Drape Eric51 | Executive VP Global Operations | Sell | 2,079 | $11.13 | $23,135.32 | -5.0% | - | - | |
| Feb 16, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Stark David Matthew53 | Exec. VP Chief Legal Officer | Sell | 3,926 | $11.12 | $43,668.51 | -56.9% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.